Differential expression of PDGFRA in glioma subtypes and its association with patient survival time.

<p>In both GSE16011 (<b>A, B</b>) and Rembrandt (<b>C, D</b>) data sets, PDGFRA expression (Mean ± 2 SEM, SEM: standard error of the mean) was highly variable among the samples of each morphological subtype (<b>A</b> and <b>C.</b> NT: non-tumor; AII, astrocytoma grade II; AIII: astrocytoma grade III; GBM, glioblastoma; OD: oligodendroglioma; OA: oligoastrocytoma). Low-grade gliomas showed significantly higher levels of PDGFRA expression compared to high-grade gliomas (<b>B</b> and <b>D</b>). Kaplan-Meier plots showed that in both GSE16011 (<b>E</b>) and Rembrandt (<b>F</b>) data sets, the survival of patients with the upper 25% PDGFRA expression (PDGFRA-high) in glioma samples irrespective of their morphological diagnosis was significantly longer compared with those glioma patients with PDGFRA expression at the lowest 25% (PDGFRA-low) and the intermediate 50% (log-rank test).